title: Allergen Immunotherapy: Vaccine Modification.
abstract: There is a need for newer therapeutic agents that improve the safety of allergen immunotherapy, provide ease of delivery to patients that fosters compliance and allows access to a greater proportion of the allergic population who could benefit from this disease-modifying treatment, and achieve an acceptable therapeutic benefit for patients committing to the treatment. The advances in sublingual allergen immunotherapy are encouraging, as this offers patients a noninjectable form of treatment of inhalant allergies. The continued research and development of the novel therapeutic constructs discussed in this article holds the promise of accomplishing the aforementioned goals in the future.
authors.affiliation: Division of Allergy & Clinical Immunology, Johns Hopkins Medicine, Baltimore, MD 21287, USA; Creticos Research Group, 1300 Saint Paul's Way, Crownsville, MD 21032, USA. Electronic address: psocrates@comcast.net.
authors.forename: Peter Socrates
authors.initials: PS
authors.lastname: Creticos
mesh_terms: D000485:Allergens / Q000737:chemistry / Q000276:immunology*; D000818:Animals; D003888:Desensitization, Immunologic; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D007073:Immunoglobulin E / Q000378:metabolism; D008407:Mast Cells / Q000276:immunology*; D010349:Patient Compliance; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000276:immunology*; D015398:Signal Transduction; D051193:Toll-Like Receptors / Q000378:metabolism; D014612:Vaccines / Q000276:immunology*
chemical_list: D000485:Allergens; D010446:Peptide Fragments; D051193:Toll-Like Receptors; D014612:Vaccines; D007073:Immunoglobulin E
keywords: Allergen immunotherapy; Allergic rhinitis; Vaccine modification